In patients with alcoholic hepatitis (AH), hepatic LCN2 expression and serum LCN2 levels both dramatically increased and were connected with disease severity and portal hypertension (45, 126, 127) LCN2 levels in the blood are a biomarker for metabolic diseases as a result and are expected to be a new therapeutic target to control appetite and obesity (8). The gene discussed is LCN2; the disease is obesity due to melanocortin 4 receptor deficiency.